Dendreon Readies For Next Provenge Hurdles: Supply And Reimbursement
Executive Summary
Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term
You may also be interested in...
Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says
Clinical research demonstrating positive health outcomes from Dendreon's prostate cancer vaccine Provenge is "moderately" strong, the Agency for Healthcare Research and Quality concludes in a draft technology assessment prepared for the upcoming meeting of the Medicare Evidence Development and Coverage Advisory Committee.
Dendreon Extends Provenge Supply In Agreement With GSK
Supply arrangement won't impact availability of Provenge this year; first shipment from GSK will begin in 2011, according to a regulatory filing.
Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says
In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company